Reduce the risk of recurrence of renal cell carcinoma by 32%

Product

Product
Supplier
Inquiry





 My ECHEMI

 EN

Reduce the risk of recurrence of renal cell carcinoma by 32%

 Last Update: 2021-06-10

 Source: Internet

 Author: User

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Merck & Co.

Renal cell carcinoma is the most common kidney cancer, accounting for 90% of the total number of kidney cancers.

Note: The original text has been deleted

Reference materials:

[1] Merck's KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC).

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Reduce the risk of recurrence of renal cell carcinoma by 32%

Related Articles

Express reduces the risk of recurrence of renal cell carcinoma by 32%, and the phase 3 results of blockbuster PD-1 inhibitors are positive